

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known		
				Application Number	10/598,965 Conf. No. 2679	
				Filing Date	February 26, 2007	
				First Named Inventor	Jean Gariepy	
				Art Unit	1639	
Examiner Name	Amber D. Steele					
Attorney Docket Number	107415-0003-101					
Sheet	1	of	6			

U.S. PATENT DOCUMENTS					
Examiner initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code ² (if known)			
		4,753,894	06-28-1988	Frankel et al.	
		5,047,513	09-10-1991	Döbeli et al.	
		5,310,683	05-10-1994	Godec et al.	
		5,354,670	10-11-1994	Nickoloff et al.	
		5,571,698	11-05-1996	Ladner et al.	
		5,659,123	08-19-1997	Van Rie et al.	
		5,869,250	02-09-1999	Cheng et al.	
		5,888,750	03-30-1999	Vanmaele et al.	
		5,922,848	07-13-1999	Vanmaele et al.	
		6,086,900	07-11-2000	Draper	
		6,833,131	12-21-2004	Smith	
		US2002/0161203	10-31-2002	Sheppard et al.	
		US2003/0188326	10-02-2003	D'Andrea et al.	

FOREIGN PATENT DOCUMENTS						
Examiner initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO 05/92917	10-06-2005	Jean Gariepy et al.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/598,965 Conf. No. 2679
				Filing Date	February 26, 2007
				First Named Inventor	Jean Gariepy
				Art Unit	1639
				Examiner Name	Amber D. Steele
				Attorney Docket Number	107415-0003-101
Sheet	2	of	6		

NON PATENT LITERATURE DOCUMENTS			
Examiner initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Bast <i>et al.</i> , "Toxicity and immunogenicity of a verotoxin 1 mutant with reduced globotriaosylceramide receptor binding in rabbits," <i>Infect Immun.</i> , 65:2019-2028 (1997).	
		Battelli, "Cytotoxicity and toxicity to animals and humans of ribosome-inactivating proteins," <i>Mini Reviews in Medicinal Chemistry</i> , 4:513-521 (2004).	
		Brigotti <i>et al.</i> , "The RNA-N-glycosidase activity of Shiga-like toxin I: kinetic parameters of the native and activated toxin," <i>Toxicon.</i> , 35:1431-1437 (1997).	
		Clark <i>et al.</i> , "Phenylalanine 30 plays an important role in receptor binding of verotoxin-1," <i>Mol. Microbiol.</i> , 19:891-899 (1996).	
		DeGrandis <i>et al.</i> , "Globotetraosylceramide is recognized by the pig edema disease toxin," <i>Journal of Biological Chemistry</i> , 264:12520-12525 (1989).	
		del Rio <i>et al.</i> , "Combinatorial libraries of proteins: Analysis of efficiency of mutagenesis techniques," <i>Biotechniques</i> , 17:1132-1139 (1994).	
		Deresiewicz <i>et al.</i> , "Mutations affecting the activity of the Shiga-like toxin I A-chain," <i>Biochemistry</i> , 31:3272-3280 (1992).	
		Eiklid <i>et al.</i> , "Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells," <i>Exp. Cell Res.</i> , 126:321-326 (1980).	
		Garred <i>et al.</i> , "Role of processing and intracellular transport for optimal toxicity of Shiga toxin and toxin mutants," <i>Exp Cell Res.</i> , 218:39-49 (1995).	
		Gendler <i>et al.</i> , "A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats," <i>J Biol Chem.</i> , 263:12820-12823 (1988).	
		Girling <i>et al.</i> , "A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas," <i>Int J Cancer</i> , 43:1072-1076 (1989).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/598,965 Conf. No. 2679
				Filing Date	February 26, 2007
				First Named Inventor	Jean Gariepy
				Art Unit	1639
				Examiner Name	Amber D. Steele
				Attorney Docket Number	107415-0003-101
Sheet	3	of	6		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		Hartley <i>et al.</i> , "Cytotoxic ribosome-inactivating lectins from plants," <i>Biochim. Biophys. Acta.</i> , 1701:1-14 (2004).	
		Hermes <i>et al.</i> , "A reliable method for random mutagenesis: the generation of mutant libraries using spiked oligonucleotide primers," <i>Gene</i> , 84:143-151 (1989).	
		Hovde <i>et al.</i> , "Evidence that glutamic acid 167 is an active-site residue of Shiga-like toxin I," <i>Proc Natl Acad Sci.</i> , 85:2568-2572 (1988).	
		Iida <i>et al.</i> , "A single amino acid substitution in B subunit of Escherichia coli enterotoxin affects its oligomer formation," <i>J. Biol Chem.</i> , 264:14065-14070 (1989).	
		Jacewicz <i>et al.</i> , "Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide," <i>J. Exp Med.</i> , 163:1391-1404 (1986).	
		Jackson <i>et al.</i> , "Functional analysis of the Shiga toxin and Shiga-like toxin type II variant binding subunits by using site-directed mutagenesis," <i>J. Bacteriol.</i> , 172:653-658 (1990).	
		Janda, "Tagged versus untagged libraries: Methods for the generation and screening of combinatorial chemical libraries," <i>PNAS</i> , 91:10779-10785 (1994).	
		Kaneda, "Gene therapy: A battle against biological barriers," <i>Current Molecular Medicine</i> , 1:493-499 (2001).	
		Kasturi <i>et al.</i> , "Alanine scanning mutagenesis identifies surface amino acids on domain II of Pseudomonas exotoxin required for cytotoxicity, proper folding, and secretion into periplasm," <i>J. of Biol. Chem.</i> , 267:23427-23433 (1992).	
		Keusch <i>et al.</i> , "Globotriaosylceramide, Gb3, is an alternative functional receptor for Shiga-like toxin 2e," <i>Infect. Immun.</i> , 63:1138-1141 (1995).	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/598,965 Conf. No. 2679
				Filing Date	February 26, 2007
				First Named Inventor	Jean Gariepy
				Art Unit	1639
				Examiner Name	Amber D. Steele
				Attorney Docket Number	107415-0003-101
Sheet	4	of	6		

NON PATENT LITERATURE DOCUMENTS			
Examiner initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Khine <i>et al.</i> , "Capping and receptor-mediated endocytosis of cell-bound verotoxin (Shiga-like toxin) 1: Chemical identification of an amino acid in the B subunit necessary for efficient receptor glycolipid binding and cellular internalization," <i>J. Cell Physiol.</i> , 161:319-332 (1994).	
		Kubota <i>et al.</i> , "Colorimetric chemosensitivity testing using sulforhodamine B," <i>Journal of Surgical Oncology</i> , 52:83-88 (1993).	
		Lacy <i>et al.</i> , "Unraveling the structures and modes of action of bacterial toxins," <i>Curr. Opin. Struct. Biol.</i> 8:778-784 (1998).	
		LaPointe <i>et al.</i> , "A role for the protease-sensitive loop region of Shiga-like toxin 1 in the retrotranslocation of its A1 domain from the endoplasmic reticulum lumen," <i>J Biol Chem.</i> , 280:23310-23318 (2005).	
		Lindgren <i>et al.</i> , "The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality," <i>Infect Immun.</i> , 62:623-31 (1994).	
		Ling <i>et al.</i> , "Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3," <i>Biochemistry</i> , 37:1777-1788 (1998).	
		Lingwood <i>et al.</i> , "Verotoxins and their glycolipid receptors," <i>Adv Lipid Res.</i> , 25:189-211 (1993).	
		Linsley <i>et al.</i> , "Monoclonal antibodies reactive with mucin glycoproteins found in sera from breast cancer patients," <i>Cancer Res.</i> , 48:2138-2148 (1988).	
		Merritt <i>et al.</i> , "AB5 toxins," <i>Curr Opin Struct Biol.</i> , 5:165-171 (1995).	
		Noren <i>et al.</i> , "Construction of high-complexity combinatorial phage display peptide libraries," <i>Methods</i> , 23:169-178 (2001).	
		Nyholm <i>et al.</i> , "Modelling of the interaction of verotoxin-I (VTI) with its glycolipid receptor globotriaosylceramide (Gb3)," <i>Int Biol Macromol.</i> , 17:199-204 (1995).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/598,965 Conf. No. 2679
				Filing Date	February 26, 2007
				First Named Inventor	Jean Gariepy
				Art Unit	1639
				Examiner Name	Amber D. Steele
				Attorney Docket Number	107415-0003-101
Sheet	5	of	6		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Nyholm <i>et al.</i> , "Two distinct binding sites for globotriaosyl ceramide on verotoxins: identification by molecular modelling and confirmation using deoxy analogues and a new glycolipid receptor for all verotoxins," <i>Chem. Biol.</i> , 3:263-275 (1996).	
		O'Brien <i>et al.</i> , "Shiga and Shiga-like toxins," <i>Microbiol Rev.</i> , 51:206-220 (1987).	
		O'Brien <i>et al.</i> , "Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis," <i>Curr Top Microbiol Immunol.</i> , 180:65-94 (1992).	
		Olsnes <i>et al.</i> , "How protein toxins enter and kill cells," <i>Cancer Treat Res.</i> , 37:39-73 (1988).	
		Perampalam <i>et al.</i> , "Designing combinatorial protein libraries based on a protein toxin template," <i>Molecular & Cellular Proteomics</i> , 2:868 (2003).	
		Perampalam, "Cell-targeted ribosome-inactivating proteins derived from protein combinatorial libraries" [Online] pages 1-158, XP002509634 Retrieved from the Internet: URL:https://tspace.library.utoronto.ca/bitstream/1807/11244/1/perampalam_subodini_20_0804_PhD_thesis.pdf> [retrieved on 2009-01-09]	
		Perera <i>et al.</i> , "Identification of three amino acid residues in the B subunit of Shiga toxin and Shiga-like toxin type II that are essential for holotoxin activity," <i>J. Bacteriol.</i> , 173:1151-1160 (1991).	
		Ready <i>et al.</i> , "Site-directed mutagenesis of ricin A-chain and implications for the mechanism of action," <i>Proteins</i> , 10:270-278 (1991).	
		Reidhaar-Olson <i>et al.</i> , "Random mutagenesis of protein sequences using oligonucleotide cassettes," <i>Methods Enzymol.</i> , 208:564-586 (1991).	
		Roberts <i>et al.</i> , "Ribosome-inactivating proteins: entry into mammalian cells and intracellular routing," <i>Mini Reviews in Medicinal Chemistry</i> , 4:505-512 (2004).	
		Sandvig <i>et al.</i> , "Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella dysenteriae 1," <i>J Cell Biol.</i> , 108:1331-1343 (1989).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/598,965 Conf. No. 2679
				Filing Date	February 26, 2007
				First Named Inventor	Jean Gariepy
				Art Unit	1639
				Examiner Name	Amber D. Steele
				Attorney Docket Number	107415-0003-101
Sheet	6	of	6		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Sandvig <i>et al.</i> , "Protein toxins: mode of action and cell entry," <i>Biochem Soc Trans.</i> , 20:724-727 (1992).	
		Sarkar <i>et al.</i> , "The "megaprimer" method of site-directed mutagenesis," <i>Biotechniques</i> , 8:404-407 (1990).	
		Skehan <i>et al.</i> , "New colorimetric cytotoxicity assay for anticancer-drug screening," <i>J Natl Cancer Inst.</i> , 82:1107-1112 (1990).	
		Smedley <i>et al.</i> , "Mutagenesis of three surface-exposed loops of a <i>Bacillus thuringiensis</i> insecticidal toxin reveals residues important for toxicity, receptor recognition and possibly membrane insertion," <i>Microbiology</i> , 142:1617-1624 (1996).	
		Stein <i>et al.</i> , "Crystal structure of the cell-binding B oligomer of verotoxin-1 from <i>E. coli</i> ," <i>Nature</i> , 355:748-750 (1992).	
		Tyrrell <i>et al.</i> , "Alteration of the carbohydrate binding specificity of verotoxins from Gal α 1-4Gal to GalNAc β 1-3Gal α 1-4Gal and vice versa by site-directed mutagenesis of the binding subunit," <i>PNAS</i> , 89:524-528 (1992).	
		Yamaizumi <i>et al.</i> , "One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell," <i>Cell</i> , 15:245-250 (1978).	
		Yamasaki <i>et al.</i> , "Importance of arginine at position 170 of the A subunit of Vero toxin 1 produced by enterohemorrhagic <i>Escherichia coli</i> for toxin activity," <i>Microb Pathog</i> , 11:1-9 (1991).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.